| Previous Close | 0.4060 |
| Open | 0.4160 |
| Bid | 0.4380 x 0 |
| Ask | 0.4780 x 0 |
| Day's Range | 0.4160 - 0.4160 |
| 52 Week Range | 0.1590 - 0.7150 |
| Volume | 5 |
| Avg. Volume | 48 |
| Market Cap | 14.636M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0870 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
COVID-19 Pandemic - The government presents its daily update
QUÉBEC CITY, Nov. 28, 2020 /CNW Telbec/ - The most recent data on the evolution of COVID-19 in Québec show 1,480 new cases, bringing the total number of people infected to 139,643.
- Newsfile
Canntab Therapeutics Announces End of Supply and Distribution Agreements with Exactus
Toronto, Ontario--(Newsfile Corp. - November 16, 2020) - Â Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis.During a time ...
- Newsfile
Canntab Announces Closing of Purchases of Cannabis Processing Equipment and Leasehold Improvements
Toronto, Ontario--(Newsfile Corp. - October 19, 2020) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that the previously announced asset purchase agreement with CMAX Technologies Inc. ("CMAX"), a related party of the Company has closed (the "CMAX Transaction"). Pursuant to the CMAX Transaction, Canntab has acquired certain cannabis-processing ...
